Prostate Cancer
News
Long-term Androgen Suppression Is Superior for Prostate Cancer
(06/22/2009)
Short-term androgen suppression produces inferior survival compared with long-term androgen suppression in the treatment of locally advanced prostate cancer, according to the results of a study published in the New England Journal of Medicine.
Denosumab Provides Bone Benefits in Prostate and Breast Cancer
(06/15/2009)
Among prostate patients treated with androgen deprivation therapy, the investigational drug denosumab increases bone density and reduces the risk of fractures. Denosumab also improves bone density in breast cancer patients treated with aromatase inhibitors. These were the results of two studies presented at the 2009 annual meeting the American Society of Clinical Oncology (ASCO).
Adjuvant Radiation Therapy Improves Outcome Among Men with pT3 Prostate Cancer
(05/19/2009)
Among men treated with radical prostatectomy and found to have pT3 prostate cancer (cancer that extends beyond the prostate capsule), adjuvant treatment with radiation therapy reduces the risk of post-treatment PSA increase. The results of this Phase III clinical trial were published in the Journal of Clinical Oncology.
Statins May Reduce Risk of Prostate Cancer
(05/11/2009)
According to the results of a study presented at the annual meeting of the American Urological Association, use of the cholesterol-lowering drugs known as statins may reduce the risk of developing prostate cancer.
More Detailed Results of Provenge® in Prostate Cancer Presented
(04/29/2009)
According to the results of the Phase III IMPACT trial, treatment with Provenge® (sipuleucel-T), an investigational immunotherapy, improved overall survival by 4.1 months among men with metastatic, androgen-independent prostate cancer. These results were presented at the 2009 annual meeting of the American Urological Association.
More
Prostate Cancer
Cancer News...